Sarepta Therapeutics Price Target Raised to $13

Citigroup boosts price target on biotech firm's stock despite recent earnings miss

Mar. 29, 2026 at 6:36am

Got story updates? Submit your updates here. ›

Sarepta Therapeutics (NASDAQ:SRPT) had its price target increased from $9 to $13 by Citigroup, though the firm maintained a 'sell' rating on the biotechnology company's stock. The target hike comes despite Sarepta reporting weaker-than-expected earnings in its latest quarter.

Why it matters

Sarepta is a leading developer of precision genetic medicines for rare neuromuscular diseases, particularly Duchenne muscular dystrophy (DMD). The company's stock price and valuation are closely watched by investors as it navigates the complex regulatory landscape for its experimental therapies.

The details

Citigroup raised its price target on Sarepta Therapeutics from $9 to $13 per share, though the firm kept a 'sell' rating on the stock. The target hike comes after Sarepta reported a wider-than-expected loss in its latest quarterly earnings. Several other research firms have also weighed in on Sarepta, with Needham & Company reiterating an 'underperform' rating, while Wall Street Zen upgraded the stock to 'hold' and HC Wainwright reiterated a 'sell' rating.

  • Sarepta reported its Q4 2025 earnings on February 25, 2026.
  • Citigroup issued its updated price target and rating on March 29, 2026.

The players

Sarepta Therapeutics

A biopharmaceutical company focused on developing precision genetic medicines for rare neuromuscular diseases, particularly Duchenne muscular dystrophy (DMD).

Citigroup

A major global investment bank that covers Sarepta Therapeutics and issued the updated price target and rating on the stock.

Got photos? Submit your photos here. ›

What they’re saying

“Sarepta Therapeutics (NASDAQ:SRPT) had its price target hoisted by Citigroup from $9.00 to $13.00 in a research report sent to investors on Thursday morning.”

— Citigroup, Research Analysts

What’s next

Investors will be closely watching to see if Sarepta can meet or exceed earnings expectations in its next quarterly report, which could impact the stock price and analyst views.

The takeaway

Sarepta's experimental therapies for rare diseases like DMD remain a focal point for biotech investors, despite the company's recent earnings miss. The updated price target from Citigroup suggests analysts see potential upside, even as the firm maintains a 'sell' rating on the stock.